Lanthanum carbonate (BAY77-1931) + Calcium carbonate
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Jan 1, 2006 → May 1, 2006
NCT ID
NCT01514851About Lanthanum carbonate (BAY77-1931) + Calcium carbonate
Lanthanum carbonate (BAY77-1931) + Calcium carbonate is a phase 3 stage product being developed by Bayer for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01514851. Target conditions include Hyperphosphatemia.
What happened to similar drugs?
2 of 14 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (12)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01514851 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperphosphatemia